1586 Oral vs intravenous antibiotics in low risk paediatric febrile neutropenia: A meta-analysis of randomised controlled trials

2015 ◽  
Vol 51 ◽  
pp. S233
Author(s):  
A. Vedi ◽  
R. Cohn
Keyword(s):  
Febrile Neutropenia ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Low Risk ◽  
Controlled Trials ◽  
Intravenous Antibiotics ◽  
Randomised Controlled

Safety of early discharge after primary angioplasty in low-risk patients with ST-segment elevation myocardial infarction: A meta-analysis of randomised controlled trials

2018 ◽  
Vol 25 (8) ◽  
pp. 807-815 ◽  
Author(s):  
Wei Gong ◽  
Aobo Li ◽  
Hui Ai ◽  
Han Shi ◽  
Xiao Wang ◽  
...  
Keyword(s):  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Early Discharge ◽  
Primary Angioplasty ◽  
Low Risk ◽  
Controlled Trials ◽  
St Segment Elevation ◽  
St Segment ◽  
Risk Patients ◽  
Randomised Controlled

Background Early discharge after successful primary angioplasty is common, but the evidence supporting the practice is still lacking. We therefore performed a meta-analysis assessing the safety of early discharge after primary angioplasty in low-risk patients with ST-segment elevation myocardial infarction (STEMI). Methods Randomised controlled trials were identified and extracted from PubMed, Embase, Cochrane Library databases and reference lists of relevant papers. Heterogeneity was analysed using the I2 test. If there was a lack of heterogeneity, fixed effects models would be used for the meta-analysis, otherwise random effects models were used. Statistical analyses were performed using Review Manager 5.3. Results Five randomised controlled trials involving 1575 STEMI patients met the criteria. Meta-analysis showed that the early discharge strategy group had a significantly shortened length of hospital stay compared to the conventional discharge strategy group (standardised mean difference −1.46, 95% confidence interval (CI) −2.04 to −0.88; P < 0.0001), and there was no difference in mortality and readmission rates between the two groups (risk ratio 0.78, 95% CI 0.50 to 1.22; P = 0.41). Conclusions The findings of this meta-analysis suggested that the early discharge strategy after successful primary angioplasty is safe among selected low-risk STEMI patients. A shorter hospital stay could benefit both the patients and the healthcare systems.

scholarly journals Cannabinoids for adult cancer-related pain: systematic review and meta-analysis

2020 ◽  
Vol 10 (1) ◽  
pp. 14-24 ◽  
Author(s):  
Elaine G Boland ◽  
Michael I Bennett ◽  
Victoria Allgar ◽  
Jason W Boland
Keyword(s):  
Systematic Review ◽  
Adverse Effects ◽  
Cancer Pain ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Mean Difference ◽  
Low Risk ◽  
Controlled Trials ◽  
Randomised Controlled

ObjectivesThere is increased interest in cannabinoids for cancer pain management and legislative changes are in progress in many countries. This study aims to determine the beneficial and adverse effects of cannabis/cannabinoids compared with placebo/other active agents for the treatment of cancer-related pain in adults.MethodsSystematic review and meta-analysis to identify randomised controlled trials of cannabinoids compared with placebo/other active agents for the treatment of cancer-related pain in adults to determine the effect on pain intensity (primary outcome) and adverse effects, including dropouts. Searches included Embase, MEDLINE, PsycINFO, Web of Science, ClinicalTrials.gov, Cochrane and grey literature. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed.ResultsWe identified 2805 unique records, of which six randomised controlled trials were included in this systematic review (n=1460 participants). Five studies were included in the meta-analysis (1442 participants). All had a low risk of bias. There was no difference between cannabinoids and placebo for the difference in the change in average Numeric Rating Scale pain scores (mean difference −0.21 (−0.48 to 0.07, p=0.14)); this remained when only phase III studies were meta-analysed: mean difference −0.02 (−0.21 to 0.16, p=0.80). Cannabinoids had a higher risk of adverse events when compared with placebo, especially somnolence (OR 2.69 (1.54 to 4.71), p<0.001) and dizziness (OR 1.58 (0.99 to 2.51), p=0.05). No treatment-related deaths were reported. Dropouts and mortality rates were high.ConclusionsStudies with a low risk of bias showed that for adults with advanced cancer, the addition of cannabinoids to opioids did not reduce cancer pain.Trial registration numberCRD42018107662.

Sign in / Sign up

Export Citation Format

Share Document